News and Updates

Congress has passed bipartisan legislation to extend and strengthen the Special Diabetes Program (SDP), a cornerstone of Federal investment in type 1 diabetes (T1D) research. The President signed the legislation and it is now law, ensuring continued momentum toward better treatments, disease-modifying therapies, and cures. This legislation: These are huge wins for the T1D community […]

Nearly 3 years after Breakthrough T1D joined forces with Civica, a non-profit pharmaceutical company, its first insulin is now available for purchase at pharmacies across the country. Check out our story from October that highlights the years of partnership between Civica and Breakthrough T1D that made today a reality. We worked with our partners at […]

How quickly a year goes by—and a lot has happened for type 1 diabetes (T1D) in 2025! In these last few weeks leading up to the new year, Breakthrough T1D would like to take a moment to reflect on how far we’ve come in the past 365 days. Read on for the greatest T1D accomplishments […]

Through grassroots support, Breakthrough T1D advocates help advance treatments, influence policy, and improve global access to care.

What is the pipeline? Every new medical device, therapy, treatment, and drug—including those for type 1 diabetes (T1D)—goes through the drug development pipeline. Getting a new therapy or device from the earliest stages of research eventually into the hands of people with T1D is a complicated process. Science takes time (from years to decades!), money […]

This past week, the FDA and Sanofi, the maker of Tzield, made an important announcement. Tzield, the first disease-modifying therapy approved for delaying onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D, has been accepted into the FDA Commissioner’s National Priority Voucher (CNPV) program for people with stage 3 T1D. […]

Nearly 3 years ago, Breakthrough T1D joined forces with Civica Rx, a non-profit pharmaceutical company, to manufacture and distribute low-cost insulins. Starting on January 1, 2026, the first of those insulins, insulin glargine-yfgn (a long-acting insulin interchangeable with Lantus®), will be available for purchase. 5 pens, no more than $55 – for anyone While we […]

Analysis compiled by Avalere Health and supported by Breakthrough T1D (formerly JDRF) finds that research funded by the Special Diabetes Program (SDP) has yielded more than $50 billion in federal healthcare savings.  Created by Congress in 1997 and administered by the National Institutes of Health (NIH), the SDP provides federal funding to support research to prevent, treat, and […]

A new Breakthrough T1D-funded study finds that people with T1D and their caregivers are largely willing to try advanced new T1D therapies.

Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.